Goldman Sachs Maintains Buy on Calumet, Raises Price Target to $24
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $20 to $24.
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Buy and raises the price target from $20 to $24.